Funding information
This work was supported by The Clinical Research Plan of Shanghai Hospital Development Center (No. SHDC2020CR3006A), National Natural Science Foundation of China (81972017), Shanghai Collaborative Innovation Center for Translational Medicine (No. TM202105) , and the Foundation of Shanghai Renji Hospital of School of Medicine of Jiaotong University (RJPY-10-005).
Reference
1. Ramos-Casals M, Brito-Zeron P, Mariette X. Systemic and organ-specific immune-related manifestations of COVID-19. Nat Rev Rheumatol. 2021 Jun;17(6):315-32.
2. Ghaebi M, Tahmasebi S, Jozghorbani M, et al. Risk factors for adverse outcomes of COVID-19 patients: Possible basis for diverse responses to the novel coronavirus SARS-CoV-2. Life Sci. 2021 Jul 15;277:119503.
3. Zhang ZL, Hou YL, Li DT, Li FZ. Diagnostic efficacy of anti-SARS-CoV-2 IgG/IgM test for COVID-19: A meta-analysis. J Med Virol. 2021 Jan;93(1):366-74.
4. Norz D, Olearo F, Perisic S, et al. Multicenter Evaluation of a Fully Automated High-Throughput SARS-CoV-2 Antigen Immunoassay. Infect Dis Ther. 2021 Dec;10(4):2371-9.
5. Padoan A, Cosma C, Sciacovelli L, et al. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clinical Chemistry and Laboratory Medicine (CCLM). 2020;58(7):1081-8.
6. Rahbari R, Moradi N, Abdi M. rRT-PCR for SARS-CoV-2: Analytical considerations. Clin Chim Acta. 2021 May;516:1-7.
7. Yang H, Chen Z, Cao X, et al. A sample-in-digital-answer-out system for rapid detection and quantitation of infectious pathogens in bodily fluids. Anal Bioanal Chem. 2018 Nov;410(27):7019-30.
8. Ivanov AV, Safenkova IV, Zherdev AV, Dzantiev BB. Recombinase Polymerase Amplification Assay with and without Nuclease-Dependent-Labeled Oligonucleotide Probe. Int J Mol Sci. 2021 Nov 2;22(21).
9. Gao J, Quan L. Current Status of Diagnostic Testing for SARS-CoV-2 Infection and Future Developments: A Review. Med Sci Monit. 2020 Dec 17;26:e928552.
10. Lai CKC, Lam W. Laboratory testing for the diagnosis of COVID-19. Biochem Biophys Res Commun. 2021 Jan 29;538:226-30.
11. Xu X, Sun J, Nie S, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med. 2020 Aug;26(8):1193-5.
12. Coutinho A, Riaz A, Makan A, et al. Lessons of the month: Co-infection with SARS-CoV-2 and influenza B virus in a patient with community-acquired pneumonia. Clin Med (Lond). 2020 Nov;20(6):e262-e3.
13. Lai CC, Wang CY, Hsueh PR. Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents? J Microbiol Immunol Infect. 2020 Aug;53(4):505-12.
14. Wu X, Cai Y, Huang X, et al. Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China. Emerg Infect Dis. 2020 Jun;26(6):1324-6.
15. Layden JE, Ghinai I, Pray I, et al. Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin - Final Report. N Engl J Med. 2020 Mar 5;382(10):903-16.
16. Zhu X, Wang X, Han L, et al. Multiplex reverse transcription loop-mediated isothermal amplification combined with nanoparticle-based lateral flow biosensor for the diagnosis of COVID-19. Biosens Bioelectron. 2020 Oct 15;166:112437.
17. Lambert-Niclot S, Cuffel A, Pape SL, et al. Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs. Journal of Clinical Microbiology. 2020;58(8):e00977-20.
TABLE 1 RPA primer set design